ProfileGDS4814 / ILMN_1814165
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 72% 69% 62% 73% 72% 66% 70% 70% 69% 69% 71% 73% 70% 70% 70% 74% 71% 72% 71% 70% 68% 72% 73% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)79.761872
GSM780708Untreated after 4 days (C2_1)70.467569
GSM780709Untreated after 4 days (C3_1)56.735562
GSM780719Untreated after 4 days (C1_2)84.830673
GSM780720Untreated after 4 days (C2_2)83.706472
GSM780721Untreated after 4 days (C3_2)62.335966
GSM780710Trastuzumab treated after 4 days (T1_1)71.654370
GSM780711Trastuzumab treated after 4 days (T2_1)72.000170
GSM780712Trastuzumab treated after 4 days (T3_1)70.985869
GSM780722Trastuzumab treated after 4 days (T1_2)69.192969
GSM780723Trastuzumab treated after 4 days (T2_2)79.141771
GSM780724Trastuzumab treated after 4 days (T3_2)86.69873
GSM780713Pertuzumab treated after 4 days (P1_1)74.613970
GSM780714Pertuzumab treated after 4 days (P2_1)72.563670
GSM780715Pertuzumab treated after 4 days (P3_1)73.06670
GSM780725Pertuzumab treated after 4 days (P1_2)89.399474
GSM780726Pertuzumab treated after 4 days (P2_2)76.29571
GSM780727Pertuzumab treated after 4 days (P3_2)79.854772
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)76.728271
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)75.060270
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)67.435368
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)80.944472
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)84.574273